Indefinite Delivery Contract SPE2DR25D9230

Award Date 9/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The key information from the provided federal contract IDV award is as follows: The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders...
The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 IDC, valid through November 2026, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter...
The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide pharmaceutical products and medical supplies to the Department of Defense (DoD) and other federal government customers. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of branded and generic prescription drugs, over-the-counter medications,...
The federal contract IDV award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, covers a wide range of pharmaceutical products and medical supplies to support the medical needs of Department of Defense (DoD) healthcare facilities and the U.S. Coast Guard. The single-award Indefinite Delivery Contract (IDC), valued at $499,999,999 and valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain is planning to issue a solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to establish Prime Vendor Contracts for worldwide pharmaceutical support to Defense Health Agency (DHA), Department of Defense (DoD) customers, the United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet. The contract will have a 30-month base period and three 30-month...
The U.S. Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and other federal government agencies. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs,...
The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. This IDC, under the SPE2DB program, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply...
The key details of this federal contract IDV award are as follows: The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, valued at $499,999,999 and valid through November 2026. This IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter...
The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain awarded a single-award Indefinite Delivery Contract (IDC) valued at up to $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, which runs through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and...
The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and other government agencies. The contract, valued at $499,999,999, is valid through November 2026 and covers an extensive portfolio of branded and generic prescription drugs, over-the-counter...

The key information from the provided materials is as follows:

The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a comprehensive range of pharmaceutical products and medical supplies to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), US Coast Guard, and US Naval Fleet. The contract, valued at $499,999,999, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, supporting both normal day-to-day operations and contingency/readiness requirements at locations within and outside the Continental United States.

This IDC was awarded under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to establish multiple primary supplier contracts to provide worldwide pharmaceutical support. The solicitation is expected to be issued in March 2024 and will remain open for 45 days, with the intention to make at least three separate regional awards on a Lowest Price Technically Acceptable (LPTA) basis. The total estimated value for all regions, including base and option periods, is $30.3 billion.

Generated 6/6/25, 10:03 AM